Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care

Pigment Cell Melanoma Res. 2023 Aug 25. doi: 10.1111/pcmr.13116. Online ahead of print.ABSTRACTLeptomeningeal disease (LMD) remains a major challenge in the clinical management of metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD continue to be excluded from almost all clinical trials. However, recent trials have demonstrated the feasibility of conducting prospective clinical trials in these patients. Further, new insights into the pathophysiology of LMD are identifying rational new therapeutic strategies. Here we present recent advances in the understanding of, and treatment options for, LMD from metastatic melanoma. We also annotate key areas of future focus to accelerate progress for this challenging but emerging field.PMID:37622466 | DOI:10.1111/pcmr.13116

Source: Pigment Cell and Melanoma Research - August 25, 2023 Category: Cytology Authors: Inna Smalley Adrienne Boire Priscilla Brastianos Harriet M Kluger Eva Hernando-Monge Peter A Forsyth Kamran A Ahmed Keiran S M Smalley Sherise Ferguson Michael A Davies Isabella C Glitza Oliva Source Type: research